<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289169</url>
  </required_header>
  <id_info>
    <org_study_id>MT01-KR16GBL401</org_study_id>
    <nct_id>NCT03289169</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines</brief_title>
  <official_title>A Single-Arm Trial, Open-label, Repeated, Long-term, Multi-center, A Phase IV Clinical Trial to Evaluate the Long-term Efficacy and Safety of Repeat Treatment With MEDITOXIN® in Treatment of Glabella Line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the long-term safety of repeated administraions of meditoxin® in the
      treatment of moderate to severe glabellar lines.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glabellar line improvement rate at maximum frown confirmed with investigator's live assessment</measure>
    <time_frame>4 weeks after final injection</time_frame>
    <description>improvement are defined as subjects with glabellar line severity of none (0) or mild (1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glabellar line improvement rate at maximum frown and rest confirmed with investigator's live assessment</measure>
    <time_frame>4 weeks after each injection</time_frame>
    <description>Glabellar line improvement rate at maximum frown and rest confirmed with investigator's live assessment at 4 weeks after each injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glabellar line improvement rate at maximum frown and rest confirmed with investigator's photo assessment</measure>
    <time_frame>4 weeks after each injection</time_frame>
    <description>Glabellar line improvement rate at maximum frown and rest confirmed with investigator's photo assessment at 4 weeks after each injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>MEDITOXIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meditoxin(Botulinum toxin type A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDITOXIN®</intervention_name>
    <description>20U of meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.</description>
    <arm_group_label>MEDITOXIN</arm_group_label>
    <other_name>Neuronox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 20 and 65

          -  Patients attaining ≥grade 2 (moderate) in the investigator's rating of the severity of
             glabella lines at maximum frown

          -  Patients who can comply with the study procedures and visit schedule

          -  Patients who voluntarily sign the informed consent

        Exclusion Criteria:

          -  Patients with medical conditions who may be at greater risk due to the administration
             of the investigational drugs (e.g.. diseases that may affect the neuromuscular action
             including Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis and
             motor neuropathy)

          -  Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis

          -  Patients who have received other procedures which may affect glabellar and forehead
             lines within 6 months

          -  Patients who have received other procedures which may affect glabellar and forehead
             lines within 6 months

          -  Patients who were injected with botulinum toxin within the past 3 months

          -  Patients with allergy or hypersensitivity to the investigational drugs or their
             components

          -  Patients who have bleeding tendency or taking anti-coagulant

          -  Female subjects who are pregnant or lactating. Female subjects of childbearing age who
             have a plan to get pregnant during the study period, or do not use available
             contraceptive methods (Women of childbearing age should have negative urine pregnancy
             test results at baseline visit (0 week) prior to the first injection.)

          -  Patients with skin disorders or infection at the injection site

          -  Patients who are participating in other clinical trials or have participated in other
             clinical trials 30 days before screening

          -  Patients who are unable to communicate or follow the instructions

          -  Patients who are not eligible for this study based on the judgment of an investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Paul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

